Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia

NCT05480501 is registered in ClinicalTrials.gov with Beijing Immunochina Medical Science & Technology Co., Ltd. as lead sponsor.

NCT NCT05480501
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05480501 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
Lead sponsor
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
July 11, 2022
Completion date
October 1, 2024
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia